Showing results (1-10 of 20) with videos related to

Sort By:
Pageof 2
The Journal of Urology|June 16, 2009
Denosumab treatment of prostate cancer with bone metastases and increased urine N-telopeptide levels after therapy with intravenous bisphosphonates: results of a randomized phase II trialKarim Fizazi, Linda Bosserman, Guozhi Gao, et al.
The Journal of Urology|December 14, 2012
Denosumab treatment of prostate cancer with bone metastases and increased urine N-telopeptide levels after therapy with intravenous bisphosphonates: results of a randomized phase II trialKarim Fizazi, Linda Bosserman, Guozhi Gao, et al.
Quality of Life Research : an International Journal of Quality of Life Aspects of Treatment, Care and Rehabilitation|October 12, 2011
The anemia impact measure (AIM): development and content validation of a patient-reported outcome measure of anemia symptoms and symptom impacts in cancer patients receiving chemotherapyLeah Kleinman, Katy Benjamin, Hema Viswanathan, et al.
Breast Cancer Research and Treatment|January 24, 2019
The characterization, management, and future considerations for ErbB-family TKI-associated diarrheaHope S Rugo, Jack A Di Palma, Debu Tripathy, et al.
Clinical Breast Cancer|November 21, 2007
Aromatase inhibitor-associated arthralgia and/ or bone pain: frequency and characterization in non-clinical trial patientsCary A Presant, Linda Bosserman, Traci Young, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 20, 2006
Randomized comparison of every-2-week darbepoetin alfa and weekly epoetin alfa for the treatment of chemotherapy-induced anemia: the 20030125 Study Group Trial, John Glaspy, Saroj Vadhan-Raj, et al.
Journal of Geriatric Oncology|January 30, 2014
Efficacy and safety of ixabepilone plus capecitabine in elderly patients with anthracycline- and taxane-pretreated metastatic breast cancerLinda T Vahdat, Eduard Vrdoljak, Henry Gómez, et al.
Clinical Lymphoma|October 15, 2003
Fourteen-day CHOP supported with granulocyte colony-stimulating factor in patients with aggressive non-Hodgkin's lymphoma: results of a phase II studyStephanie A Gregory, Delvyn C Case, Linda Bosserman, et al.
Plos One|May 30, 2015
Application of a drug-induced apoptosis assay to identify treatment strategies in recurrent or metastatic breast cancerLinda Bosserman, Karl Rogers, Carl Willis, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 4, 2007
Efficacy and safety of ixabepilone (BMS-247550) in a phase II study of patients with advanced breast cancer resistant to an anthracycline, a taxane, and capecitabineEdith A Perez, Guillermo Lerzo, Xavier Pivot, et al.
Pageof 2